Cargando…
Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein
Tumors have evolved elaborate mechanisms for evading immune detection, such as production of immunoinhibitory cytokines and down-regulation of major histocompatibility complex (MHC) expression. We have studied PAX3-FKHR as an example of an oncogenic fusion protein associated with an aggressive metas...
Autores principales: | Nabarro, Stephen, Himoudi, Nourredine, Papanastasiou, Antigoni, Gilmour, Kimberly, Gibson, Sian, Sebire, Neil, Thrasher, Adrian, Blundell, Michael P., Hubank, Mike, Canderan, Glenda, Anderson, John |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212991/ https://www.ncbi.nlm.nih.gov/pubmed/16287709 http://dx.doi.org/10.1084/jem.20050730 |
Ejemplares similares
-
Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR–dependent motility in alveolar rhabdomyosarcoma cells
por: Liu, Lingling, et al.
Publicado: (2012) -
Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
por: Anderson, J, et al.
Publicado: (2001) -
Too much AKT turns PAX3-FKHR dead: A prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma
por: Jothi, Mathivanan, et al.
Publicado: (2012) -
Structural and Functional Studies of FKHR-PAX3, a Reciprocal Fusion Gene of the t(2;13) Chromosomal Translocation in Alveolar Rhabdomyosarcoma
por: Hu, Qiande, et al.
Publicado: (2013) -
Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options
por: Brown, Robert E., et al.
Publicado: (2016)